The Orphan Drug Act and rare cancers: a retrospective analysis of oncologic orphan drug designations and associated approvals from 1983-2022

References

• National cancer institute surveillance E, and end results program cancer stat facts: common cancer sites. 2023. Available from: https://seer.cancer.gov/statfacts/html/common.html
   Google Scholar
• American Cancer Society. Cancer facts & figures. 2022. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf
   Google Scholar
• Henley SJ, Singh SD, King J, et al. Invasive cancer incidence and survival-united states 2012 morbidity and mortality weekly report (MMWR): Centers for Disease Control and Prevention; 2015. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6449a1.htm
   Google Scholar
• Centers for Disease Control and Prevention. An update on cancer deaths in the United States. 2022. Available from: https://www.cdc.gov/cancer/dcpc/research/update-on-cancer-deaths/index.htm
   Google Scholar
• McDowell S. Understanding cancer death rates: American Cancer Society; 2019. Available from: https://www.cancer.org/research/acs-research-news/understanding-cancer-death-rates.html
   Google Scholar
• American Cancer Society. Cancer prevention & early detection facts & figures 2023–2024. 2023. Available from: https://www.cancer.org/research/cancer-facts-statistics/cancer-prevention-early-detection.html
   Google Scholar
• Scott EC, Baines AC, Gong Y, et al. Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat Rev Drug Discov. 2023;22(8):625–640. doi: 10.1038/s41573-023-00723-4
   PubMed Web of Science ®Google Scholar
• American Cancer Society. How targeted therapies are used to treat cancer. 2021. Available from: https://www.cancer.org/cancer/managing-cancer/treatment-types/targeted-therapy/what-is.html
   Google Scholar
• Miller KL, Lanthier M. Trends in orphan new molecular entities, 1983–2014: half were first in class, and rare cancers were the most frequent target. Health Aff. 2016;35(3):464–470.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer facts & fi gures 2017-special section: rare cancers in adults. 2017. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017-special-section-rare-cancers-in-adults.pdf
   Google Scholar
• Pub. L. No. 97-414(Jan 4, 1983).
   Google Scholar
• 21 U.S.C. 360bb(a)(2).
   Google Scholar
• National Cancer Institute Division of Cancer Control & Population Sciences. Measures of cancer prevalence. 2023. Available from: https://surveillance.cancer.gov/prevalence/measures.html#complete
   Google Scholar
• Patel S, Miller Needleman KI. FDA’s office of orphan products development: providing incentives to promote the development of products for rare diseases. J Pharmacokinet Pharmacodyn. 2019;46(5):387–393. doi: 10.1007/s10928-019-09645-4
   PubMed Web of Science ®Google Scholar
• 21CFR316.20.
   Google Scholar
• Miller KL, Fermaglich LJ, Maynard J. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis. 2021;16(1):265. doi: 10.1186/s13023-021-01901-6
   PubMed Web of Science ®Google Scholar
• Stockklausner C, Lampert A, Hoffmann GF, et al. Novel treatments for rare cancers: the U.S. orphan drug act is delivering-a cross-sectional analysis. Oncology. 2016;21(4):487–493. doi: 10.1634/theoncologist.2015-0397
   Google Scholar
• Bridget Silverman. FDA’s novel approvals again led by oncology and neurology, but dermatology also shone in 2022: pink sheet pharma intelligence. 2023. Available from: https://pink.pharmaintelligence.informa.com/PS147589/FDAs-Novel-Approvals-Again-Led-By-Oncology-And-Neurology-But-Dermatology-Also-Shone-In-2022?utm_source=dailyem&utm_medium=email&utm_term=&utm_campaign=&utm_medium=email&utm_source=sfmc&utm_campaign=Pink+Sheet+Daily+(Tues±Fri)&utm_id=4547902&sfmc_id=124906171
   Google Scholar
• Fermaglich LJ, Miller KL. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the orphan drug act. Orphanet J Rare Dis. 2023;18(1):163.
   PubMed Web of Science ®Google Scholar
• U.S Food & Drug Administration. Search orphan drug designations and approvals. Available from: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm
   Google Scholar
• Vasilevsky NA, Matentzoglu NA, Toro S, et al. Mondo: unifying diseases for the world, by the world. medRxiv. 2022;2022.04.13.22273750.
   Google Scholar
• National cancer institute surveillance E, and end results program site recode ICD-0-3/WHO 2008 definition. Available from: https://seer.cancer.gov/siterecode/icdo3_dwhoheme/
   Google Scholar
• U.S Food & Drug Administration. Tissue agnostic drug development in oncology guidance for industry. 2022. p. 16.
   Google Scholar
• 21CFR316.3(b)(13).
   Google Scholar
• Zhong L, Li Y, Xiong L, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6(1):201. doi: 10.1038/s41392-021-00572-w
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. NCI budget and appropriations. 2022. Available from: https://www.cancer.gov/about-nci/budget.
   Google Scholar
• Polite BN, Ward JC, Cox JV, et al. Payment for oncolytics in the United States: a history of buy and bill and proposals for reform. J Oncol Pract. 2014;10(6):357–362. doi: 10.1200/JOP.2014.001958
   PubMedGoogle Scholar
• de Souza JA, de Lima Lopes G Jr. Medicare reimbursement changes and the practice of oncology: understanding of the past is a key to the future. J Oncol Pract. 2011;7(5):306–308. doi: 10.1200/JOP.2010.000043
   PubMedGoogle Scholar
• Bachireddy P, Burkhardt UE, Rajasagi M, et al. Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer. 2015;15(4):201–215. doi: 10.1038/nrc3907
   PubMed Web of Science ®Google Scholar
• Upton DH, Ung C, George SM, et al. Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy. Theranostics. 2022;12(10):4734–4752. doi: 10.7150/thno.69682
   PubMed Web of Science ®Google Scholar
• Noch EK, Ramakrishna R, Magge R. Challenges in the treatment of glioblastoma: multisystem mechanisms of therapeutic resistance. World Neurosurg. 2018;116:505–517. doi: 10.1016/j.wneu.2018.04.022
   PubMed Web of Science ®Google Scholar
• Gimple RC, Bhargava S, Dixit D, et al. Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes Dev. 2019;33(11–12):591–609. doi: 10.1101/gad.324301.119
   PubMed Web of Science ®Google Scholar
• Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6(4):321–337. doi: 10.1177/1756283X13478680
   PubMed Web of Science ®Google Scholar
• Aldape K, Brindle KM, Chesler L, et al. Challenges to curing primary brain tumours. Nat Rev Clin Oncol. 2019;16(8):509–520. doi: 10.1038/s41571-019-0177-5
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Reichert JM, Feldman L, et al. Clinical approval success rates for investigational cancer drugs. Clin Pharmacol Ther. 2013;94(3):329–335. doi: 10.1038/clpt.2013.117
   PubMed Web of Science ®Google Scholar